Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?

The stock of Vertex Pharmaceuticals Incorporated (VRTX) has declined almost 13% in the past six months.A key reason for the stock price decline was unimpressive data from a phase II study on its key pipeline candidate, suzetrigine, for painful lumbosacral radiculopathy (LSR), a form of peripheral neuropathic pain, which showed largely undifferentiated pain reduction from placebo. Despite the unimpressive data in phase II, management decided to forge ahead to a phase III study in this indication, which is co ...